Paydirt
CA
Insider

Christopher Richard Anzalone

Chief Executive Officer

Christopher Richard Anzalone (Chief Executive Officer) filed 5 Form 4 reports in the trailing twelve months (0 purchases, 5 sales), most often in Arrowhead Pharmaceuticals, Inc. (ARWR). The largest single filing was $12.2M of ARWR (181,832 sh across 9 lots, as filed), executed Dec 15 2025.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
returns measure stock purchases only
Filings, ttm
5
0 buys · 5 sells
Median delay
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$23.7M
shares × price, as filed
Last traded
Jan 2
Filed Jan 5

Median ADV $181.7M across their filed names

Open performance
Volume by month
$22.8M$11.4M$0Oct 2024Apr 2025Oct 2025Apr 2026Dec 2024 · sells $814KJan 2025 · sells $219KMar 2025 · sells $6.0MApr 2025 · sells $1.5MDec 2025 · sells $22.8MJan 2026 · sells $872K
Buys $0 Sells $32.3M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Healthcare 5 filings

Sector per market data · by filing · past 12 months

Most traded names
ARWR Arrowhead Pharmaceuticals, Inc. ARWR · 0 buys · 11 sells 11 filings
Recent filings
ARWRSALE Arrowhead Pharmaceuticals, Inc. View filing → $219K
11,520 sh × $19.05
Exec Jan 2 2025
Filed Jan 6 2025 · 5:30 PM ET
ARWRSALE Arrowhead Pharmaceuticals, Inc. View filing → $246K
12,563 sh × $19.59
Exec Dec 23 2024
Filed Dec 23 2024 · 5:30 PM ET
ARWRSALE Arrowhead Pharmaceuticals, Inc. View filing → $567K
26,712 sh across 3 lots
Exec Dec 18 2024
Filed Dec 20 2024 · 5:30 PM ET